The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Investigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treated patients (pts) with renal cell carcinoma (RCC).
H. A. Ball
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Y. Lin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Z. Xue
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
B. Suttle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
C. Xu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. Huang
Research Funding - GlaxoSmithKline
L. McCann
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
T. E. Hutson
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
C. N. Sternberg
Honoraria - GlaxoSmithKline
L. N. Pandite
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline